Illumina
Illumina is a developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. Illumina has developed a line of DNA sequencing technology products that address the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests.
Illumina Company ProfileÂ
Â
President & CEO: Francis deSouza
CEO photo:
Website: www.illumina.com
Ticker symbol: ILMN
Headquarters: San Diego, CA
Illumina employees: 5,500+ globally
Revenues: $2.4 Billion USD in 2016
Founded: 1998
Founders: Larry Bock, Anthony Czarnik, David Walt, Mark Chee, John Stuelpnagel
Â
Illumina NewsÂ
Illumina, Qiagen, Columbia University Near Settlement in Patent Infringement Case
It is unclear whether the impending settlement will affect all the litigation between the two sides, across several legal venues.
Illumina, Belgium Genetic Centers Partner on WGS-Based Diagnostics; Evercore Upgrades Illumina Shares
The San Diego-based sequencing technology firm is also launching noninvasive prenatal genetic testing on the VeriSeq v2 platform in Thailand.
Illumina, Roche Agree to Settle NIPT Patent Lawsuits
The settlement will end a patent battle that has raged since 2012, but the terms have not yet been disclosed.
Illumina, Microba Life Sciences Partner on Human Gut Microbiome Research
The partners will combine Illumina's next-generation sequencing technology with Australia-based Microba Life Science's microbiome analysis platform.